General Information


We are a clinical stage biopharmaceutical company with a late-stage program in Alzheimer’s disease and a discovery platform of small molecules for the inhibition of protein misfolding and aggregation in neurodegenerative disorders. Protein misfolding is an abnormal process in which a protein fails to fold in its normal configuration, rendering the protein toxic or inactive. Our goal is to develop disease modifying treatments for patients with Alzheimer’s and other neurological disorders by leveraging our expertise in inhibiting protein misfolding and aggregation.

Employees: 6
Founded: 2013
Contact Information
Address 111 Speen Street, Suite 306, Framingham, MA 01701, US
Phone Number (508) 861-7709
Web Address
View Prospectus: Alzheon
Financial Information
Market Cap $81.3mil
Revenues $0 mil (last 12 months)
Net Income $-7.6 mil (last 12 months)
IPO Profile
Symbol ALZH
Exchange NASDAQ
Shares (millions): 6.0
Price range $5.00 - $5.00
Est. $ Volume $30.0 mil
Manager / Joint Managers ThinkEquity (A division of Fordham Financial Management)/ H.C. Wainwright & Co.
CO-Managers The Benchmark Company
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change